Pharmaceutical

Vical (Nasdaq:VICL) today announced a restructuring to conserve capital and to focus its efforts on VL-2397, its antifungal drug product candidate which is entering a pivotal Phase 2 clinical trial in the first quarter of 2018, and on completing its Phase 2 HSV-2 clinical trial. As quoted in the press release: “We have carefully evaluated …

Vical (Nasdaq:VICL) today announced a restructuring to conserve capital and to focus its efforts on VL-2397, its antifungal drug product candidate which is entering a pivotal Phase 2 clinical trial in the first quarter of 2018, and on completing its Phase 2 HSV-2 clinical trial.
As quoted in the press release:

“We have carefully evaluated our organization and priorities and are restructuring to extend our cash runway to ensure that our promising HSV-2 vaccine candidate and VL-2397 antifungal drug product candidate is adequately resourced to maximize shareholder value,” said Vijay Samant, Vical’s President and Chief Executive Officer.

Click here to read the full press release.

Featured

MARKETS

Markets
TSX20383.75+97.55
TSXV701.74+1.08
DOW32120.28+191.66
S&P 5003978.73+37.25
NASD11434.74+170.29
ASX7155.20+26.40

COMMODITIES

Commodities
Gold1845.55-8.50
Silver21.79-0.20
Copper4.24-0.02
Palladium2005.00+7.00
Platinum941.77-5.22
Oil110.94+0.61
Heating Oil3.77+0.02
Natural Gas9.05+0.08

DOWNLOAD FREE REPORTS

×